Augmentin, a combination of amoxicillin and clavulanate potassium, maintained its top-selling brand status in the Indian pharmaceutical market, selling around Rs 75-80 crore per month. The strong ...

Four of the top 5 selling products of GSK are antibiotics (Augmentin, Duricef, Ceporex and Velosef). Two of them come from BMS. By having four well established - and relatively old - antibiotic ...

For further results highlights, click. GlaxoSmithKline Pharma has been benefitting from rising market share for its antibiotic Augmentin and respiratory drugs Nucala and Trelegy. Strong demand for ...

Augmentin tablets. WHO has issued an alert that ... to be a close imitation of the genuine product manufactured by GSK (GlaxoSmithKline),” WHO said in a statement. WHO says it has informed ...

with flagship brands such as Augmentin, Ceftum, and T-Bact gaining market share in the general medicines segment. Additionally, GSK’s innovative respiratory portfolio, led by Nucala and Trelegy ...

GSK Pharma’s flagship brands within the general medicines portfolio including Augmentin, Ceftum, and T-bact strengthened their market positions with share gains. The company’s innovative ...

Say Manufacturers Ready To Bridge Impact Of GSK, Others Exit From Nigeria Nigerian Pharmaceutical companies are beginning to ...

India's GlaxoSmithKline Pharma reports higher profit ... led by sustained demand for its respiratory drugs and antibiotic Augmentin. February 5, 2025 Abbott India posts higher Q3 profit on strong ...

GlaxoSmithKline Pharmaceuticals Ltd (GSK ... Flagship brands within the general medicines portfolio including Augmentin, Ceftum, and T-bact strengthened their market positions with share gains.